Status | In progress |
Process | STA pre-2018 |
ID number | 974 |
Project Team
Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@nice.org.uk
Evidence Review Group / Assessment Group | Southampton Health Technology Assessments Centre |
Consultees
Companies sponsors | Janssen |
Others | Department of Health |
NHS England | |
Welsh Government | |
Patient carer groups | Bloodwise |
Myeloma UK | |
Professional groups | Association of Cancer Physicians |
Cancer Research UK | |
Royal College of Physicians | |
Royal College of Radiologists | |
UK Myeloma Forum |
Commentators
Associated public health groups | Public Health England |
Public Health Wales | |
Comparator companies | Amgen (carfilzomib) |
Celgene (lenalidomide and pomalidomide) | |
Concordia International (dexamethasone) | |
Dr Reddy’s Laboratories (bendamustine) (not participating) | |
Janssen (bortezomib, daratumumab and doxorubicin) | |
Medac UK (bendamustine, doxorubicin) (not participating) | |
Napp Pharmaceuticals (bendamustine) (not participating) | |
Novartis (panobinostat) | |
Zentiva (bendamustine) (not participating) | |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Bloodwise |
Institute of Cancer Research | |
National Cancer Research Institute |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
06 November 2018 | Committee meeting: 2 |
12 July 2018 - 02 August 2018 | Appraisal consultation: 1 |
06 June 2018 | Committee meeting: 1 |
03 January 2018 | Invitation to participate |
02 August 2016 - 31 August 2016 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
08 June 2016 | Referral |
08 June 2016 | In progress, Topic referred |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance